~~<i id='FA5114B47C'><strike id='FA5114B47C'><tt id='FA5114B47C'><pre id='FA5114B47C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

author：focus 2025-09-06 03:58:25 - browse：98721

the shape of a medical note connected by dots and lines — health tech coverage from STAT — Adobe

In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers.

But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI? Can it be used at all to make decisions about the coverage of older patients? If so, how?

This week, the federal agency that oversees Medicare sought to boil it all down into a simple directive: Put the circumstances of the individual patient first, and your algorithm second.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Sanofi strikes deal with Novavax, boosting the vaccine maker

entertainment

knowledge

explore

entertainment

focus

leisure time

MichaelConroy/APThesedays,thesurefirewaytogetaheadinhealthinsuranceistobecomeahealthcareprovider,and

WSS

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Readout: Friday, Oct. 20 biotech updates

Why a market frenzy over new weight loss drugs defies logic

Results on Novartis prostate cancer therapy could expand its use

FDA clears Verve to begin U.S. study of gene

Study: People of West African ancestry at greater risk of cardiac amyloidosis

knowledge

knowledge

entertainment

How to save PrEP access — and even expand it

STAT Summit: How researchers deal with rejection

How one medical school became remarkably diverse

Roche drug slashes death risk in early

DIEP, the 'gold standard' of breast reconstruction, is under threat

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Novavax promises a turnaround & Lilly roils the obesity market

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Malaria cases in Florida and Texas: Here’s what you need to know

CZI to create biohub to build anti

knowledge

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Roivant's CEO is a star, but biotech's black hole persists

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Brain worms: The science behind RFK Jr.'s parasitic infection

Cassava Sciences’ Alzheimer’s clinical trials should be halted

How AI can help patients find reliable information about doctors

explore

entertainment

focus

leisure time